62 related articles for article (PubMed ID: 29113409)
1. Phase I clinical trial of AXL1717 for treatment of relapsed malignant astrocytomas: analysis of dose and response.
Aiken R; Axelson M; Harmenberg J; Klockare M; Larsson O; Wassberg C
Oncotarget; 2017 Oct; 8(46):81501-81510. PubMed ID: 29113409
[TBL] [Abstract][Full Text] [Related]
2. Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial.
Paller CJ; Zhou XC; Heath EI; Taplin ME; Mayer T; Stein MN; Bubley GJ; Pili R; Hudson T; Kakarla R; Abbas MM; Anders NM; Dowling D; King S; Bruns AB; Wagner WD; Drake CG; Antonarakis ES; Eisenberger MA; Denmeade SR; Rudek MA; Rosner GL; Carducci MA
Clin Cancer Res; 2018 Jan; 24(2):306-315. PubMed ID: 29113986
[No Abstract] [Full Text] [Related]
3. Structural Models for a Series of Allosteric Inhibitors of IGF1R Kinase.
Verma J; Vashisth H
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791406
[TBL] [Abstract][Full Text] [Related]
4. IGF-1R targeting in cancer - does sub-cellular localization matter?
Soni UK; Jenny L; Hegde RS
J Exp Clin Cancer Res; 2023 Oct; 42(1):273. PubMed ID: 37858153
[TBL] [Abstract][Full Text] [Related]
5. Drugging IGF-1R in cancer: New insights and emerging opportunities.
Wang P; Mak VC; Cheung LW
Genes Dis; 2023 Jan; 10(1):199-211. PubMed ID: 37013053
[TBL] [Abstract][Full Text] [Related]
6. Brain Tumor Networks in Diffuse Glioma.
Yang Y; Schubert MC; Kuner T; Wick W; Winkler F; Venkataramani V
Neurotherapeutics; 2022 Oct; 19(6):1832-1843. PubMed ID: 36357661
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Options in Neuro-Oncology.
Afonso M; Brito MA
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628161
[TBL] [Abstract][Full Text] [Related]
8. Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of targeted therapies and immunotherapies in the management of progressive glioblastoma.
Winograd E; Germano I; Wen P; Olson JJ; Ormond DR
J Neurooncol; 2022 Jun; 158(2):265-321. PubMed ID: 34694567
[TBL] [Abstract][Full Text] [Related]
9. Unraveling the IGF System Interactome in Sarcomas Exploits Novel Therapeutic Options.
Mancarella C; Morrione A; Scotlandi K
Cells; 2021 Aug; 10(8):. PubMed ID: 34440844
[TBL] [Abstract][Full Text] [Related]
10. Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma.
Bolcaen J; Nair S; Driver CHS; Boshomane TMG; Ebenhan T; Vandevoorde C
Pharmaceuticals (Basel); 2021 Jun; 14(7):. PubMed ID: 34209513
[TBL] [Abstract][Full Text] [Related]
11. A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials.
Cruz Da Silva E; Mercier MC; Etienne-Selloum N; Dontenwill M; Choulier L
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33918704
[TBL] [Abstract][Full Text] [Related]
12. Disrupting Insulin and IGF Receptor Function in Cancer.
Cao J; Yee D
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33429867
[TBL] [Abstract][Full Text] [Related]
13. Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives.
Birzu C; French P; Caccese M; Cerretti G; Idbaih A; Zagonel V; Lombardi G
Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33375286
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic State and Cell Identity Combinatorially Dictate the Susceptibility of Cells within Glioma Development Hierarchy to IGF1R Targeting.
Tian A; Kang B; Li B; Qiu B; Jiang W; Shao F; Gao Q; Liu R; Cai C; Jing R; Wang W; Chen P; Liang Q; Bao L; Man J; Wang Y; Shi Y; Li J; Yang M; Wang L; Zhang J; Hippenmeyer S; Zhu J; Bian X; Wang YJ; Liu C
Adv Sci (Weinh); 2020 Nov; 7(21):2001724. PubMed ID: 33173731
[TBL] [Abstract][Full Text] [Related]
15. Blockade of IGF/IGF-1R signaling axis with soluble IGF-1R mutants suppresses the cell proliferation and tumor growth of human osteosarcoma.
Cao D; Lei Y; Ye Z; Zhao L; Wang H; Zhang J; He F; Huang L; Shi D; Liu Q; Ni N; Pakvasa M; Wagstaff W; Zhao X; Fu K; Tucker AB; Chen C; Reid RR; Haydon RC; Luu HH; He TC; Liao Z
Am J Cancer Res; 2020; 10(10):3248-3266. PubMed ID: 33163268
[TBL] [Abstract][Full Text] [Related]
16. Glioma Cells With Genetically Engineered IGF-I Receptor Downregulation Can Persist in the Brain in a Dormant State.
Samani AA; Nalbantoglu J; Brodt P
Front Oncol; 2020; 10():555945. PubMed ID: 33072581
[TBL] [Abstract][Full Text] [Related]
17. The Role of Tyrosine Kinases as a Critical Prognostic Parameter and Its Targeted Therapies in Ewing Sarcoma.
Jin W
Front Cell Dev Biol; 2020; 8():613. PubMed ID: 32754598
[TBL] [Abstract][Full Text] [Related]
18. Pericyte-secreted IGF2 promotes breast cancer brain metastasis formation.
Molnár K; Mészáros Á; Fazakas C; Kozma M; Győri F; Reisz Z; Tiszlavicz L; Farkas AE; Nyúl-Tóth Á; Haskó J; Krizbai IA; Wilhelm I
Mol Oncol; 2020 Sep; 14(9):2040-2057. PubMed ID: 32534480
[TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy.
Hua H; Kong Q; Yin J; Zhang J; Jiang Y
J Hematol Oncol; 2020 Jun; 13(1):64. PubMed ID: 32493414
[TBL] [Abstract][Full Text] [Related]
20. Glioblastoma: Pathogenesis and Current Status of Chemotherapy and Other Novel Treatments.
Rajaratnam V; Islam MM; Yang M; Slaby R; Ramirez HM; Mirza SP
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32290213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
